Prinston Pharmaceutical Inc.

Prinston Pharmaceutical Inc. (often shortened to "Prinston") is a privately held generic pharmaceutical company headquartered at 700 Atrium Drive, Somerset, New Jersey (previously Cranbury, NJ). It was founded in 2009 and launched its first US product, benazepril, in 2010. Prinston is not publicly traded; it is a subsidiary of China-based Zhejiang Huahai Pharmaceutical Co., Ltd., which holds roughly 93.5% indirectly through PrinJohnson Biopharm, Inc. It is a small operation — third-party business databases estimate headcount in the 50–200 range, and revenue estimates in the low tens of millions are inconsistent across sources and should be treated as unreliable.

Prinston develops, files, and holds Abbreviated New Drug Applications (ANDAs) and commercializes generic prescription drugs. Its stated focus is difficult-to-make sterile and non-sterile dosage forms, including injectables and topicals, plus oral solids in cardiovascular, central nervous system, and pain-management categories. Products are marketed and distributed in the US through its wholly owned subsidiary Solco Healthcare US, LLC (acquired 2012), which sells to retail pharmacies, wholesalers, distributors, and group purchasing organizations. R&D sits in Somerset, NJ and Shanghai; manufacturing is conducted at Zhejiang Linhai, China and Charlotte, NC. The company has reported more than 75 products under development or on file with US regulators.

On litigation posture, Prinston is an operating company, not a patent assertion entity. In the tracked data it appears in exactly one case, as a defendant (0 as plaintiff), consistent with a generic manufacturer being sued by brand owners over ANDA filings rather than asserting patents itself.

That single tracked matter is Merck Sharp & Dohme LLC v. Prinston Pharmaceutical Inc., C.A. 1:22-cv-01071 (D. Del., filed Aug. 15, 2022, Judge Richard G. Andrews), a Hatch-Waxman action over U.S. Patent No. 7,326,708 arising from Prinston's ANDA No. 216886 for generic sitagliptin phosphate tablets, a version of Merck's JANUVIA. The case was flagged as related to MDL 19-md-2902. The venue is Delaware — where Prinston is incorporated and has consented to jurisdiction — not the Eastern District of Texas.